| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Brazil | 23 | 2021 | 12582 | 0.65 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 952 | 0.61 | Why? |
| Subarachnoid Hemorrhage | 2 | 2018 | 611 | 0.57 | Why? |
| Disease Notification | 1 | 2020 | 639 | 0.54 | Why? |
| Hospital Mortality | 10 | 2021 | 22087 | 0.47 | Why? |
| Critical Illness | 7 | 2021 | 17281 | 0.47 | Why? |
| Inflammation Mediators | 3 | 2020 | 2654 | 0.46 | Why? |
| Hemoglobins | 1 | 2018 | 958 | 0.46 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.41 | Why? |
| Sofosbuvir | 4 | 2021 | 518 | 0.41 | Why? |
| Cerebral Hemorrhage | 1 | 2018 | 820 | 0.41 | Why? |
| Residence Characteristics | 1 | 2021 | 1927 | 0.40 | Why? |
| Intensive Care Units | 19 | 2021 | 29594 | 0.38 | Why? |
| Sepsis-Associated Encephalopathy | 2 | 2018 | 10 | 0.36 | Why? |
| Delirium | 4 | 2018 | 1061 | 0.35 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.34 | Why? |
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2007 | 36 | 0.34 | Why? |
| Zika Virus | 5 | 2017 | 1924 | 0.34 | Why? |
| Oxidative Stress | 2 | 2018 | 2050 | 0.33 | Why? |
| Brain | 5 | 2018 | 5133 | 0.33 | Why? |
| Cognitive Dysfunction | 2 | 2019 | 1389 | 0.33 | Why? |
| Inflammation | 7 | 2021 | 13255 | 0.33 | Why? |
| Visitors to Patients | 3 | 2018 | 671 | 0.32 | Why? |
| African Americans | 1 | 2021 | 3363 | 0.29 | Why? |
| Family Relations | 2 | 2018 | 288 | 0.29 | Why? |
| HIV Infections | 3 | 2019 | 11620 | 0.27 | Why? |
| Machine Learning | 1 | 2021 | 4395 | 0.27 | Why? |
| Cardiovascular Diseases | 2 | 2019 | 11497 | 0.26 | Why? |
| Mammaplasty | 2 | 2017 | 224 | 0.26 | Why? |
| Healthcare Disparities | 1 | 2021 | 3893 | 0.25 | Why? |
| Lipopolysaccharides | 2 | 2018 | 848 | 0.24 | Why? |
| Aging | 1 | 2018 | 3581 | 0.22 | Why? |
| P-Selectin | 2 | 2020 | 224 | 0.21 | Why? |
| Lipid Droplets | 1 | 2020 | 75 | 0.21 | Why? |
| Disease Models, Animal | 2 | 2019 | 10998 | 0.21 | Why? |
| Zika Virus Infection | 4 | 2017 | 1920 | 0.21 | Why? |
| Platelet Activation | 3 | 2020 | 660 | 0.21 | Why? |
| Dengue Virus | 2 | 2017 | 910 | 0.20 | Why? |
| Hemopexin | 1 | 2018 | 5 | 0.19 | Why? |
| Monocytes | 3 | 2020 | 2978 | 0.18 | Why? |
| Respiration, Artificial | 5 | 2021 | 22116 | 0.18 | Why? |
| Leprosy, Lepromatous | 1 | 2018 | 22 | 0.18 | Why? |
| Atazanavir Sulfate | 1 | 2020 | 213 | 0.18 | Why? |
| Thromboplastin | 1 | 2020 | 275 | 0.18 | Why? |
| Chemokine CCL5 | 1 | 2018 | 169 | 0.18 | Why? |
| Erythema Nodosum | 1 | 2018 | 38 | 0.18 | Why? |
| Pectoralis Muscles | 1 | 2017 | 21 | 0.17 | Why? |
| Haloperidol | 1 | 2018 | 78 | 0.17 | Why? |
| Deep Sedation | 1 | 2019 | 121 | 0.17 | Why? |
| Neuroanatomy | 1 | 2017 | 20 | 0.17 | Why? |
| Blood Platelets | 2 | 2020 | 1704 | 0.17 | Why? |
| Heme | 1 | 2018 | 110 | 0.17 | Why? |
| Yellow fever virus | 1 | 2019 | 205 | 0.16 | Why? |
| Brain Infarction | 1 | 2018 | 129 | 0.16 | Why? |
| Platelet Aggregation | 1 | 2018 | 318 | 0.16 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.15 | Why? |
| Yellow Fever | 1 | 2019 | 231 | 0.15 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.15 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.15 | Why? |
| Thrombin | 1 | 2018 | 325 | 0.15 | Why? |
| Fetal Diseases | 1 | 2017 | 182 | 0.15 | Why? |
| Blood Coagulation Disorders | 2 | 2020 | 2040 | 0.15 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.14 | Why? |
| Geography | 1 | 2021 | 1801 | 0.14 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.14 | Why? |
| Alanine Transaminase | 1 | 2021 | 1329 | 0.14 | Why? |
| Humans | 48 | 2021 | 930598 | 0.14 | Why? |
| Patient Admission | 3 | 2021 | 5250 | 0.14 | Why? |
| Adult | 21 | 2021 | 244371 | 0.13 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.13 | Why? |
| Breast Neoplasms | 3 | 2017 | 3633 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Aspartate Aminotransferases | 1 | 2021 | 1394 | 0.13 | Why? |
| CD4 Lymphocyte Count | 1 | 2019 | 1517 | 0.13 | Why? |
| Lovastatin | 1 | 2012 | 11 | 0.13 | Why? |
| Neutrophil Activation | 1 | 2017 | 510 | 0.13 | Why? |
| Malaria, Cerebral | 1 | 2012 | 37 | 0.13 | Why? |
| Checklist | 1 | 2019 | 714 | 0.12 | Why? |
| Prospective Studies | 13 | 2021 | 43301 | 0.12 | Why? |
| Male | 19 | 2021 | 367725 | 0.12 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.12 | Why? |
| Female | 21 | 2021 | 380317 | 0.12 | Why? |
| Fluid Therapy | 1 | 2017 | 628 | 0.12 | Why? |
| Drug Resistance, Viral | 1 | 2019 | 1083 | 0.12 | Why? |
| Length of Stay | 5 | 2021 | 11042 | 0.12 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.12 | Why? |
| Fluorodeoxyglucose F18 | 2 | 2017 | 1153 | 0.12 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.12 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 533 | 0.11 | Why? |
| Neoadjuvant Therapy | 1 | 2014 | 554 | 0.11 | Why? |
| Mitochondria | 1 | 2018 | 857 | 0.11 | Why? |
| HIV | 1 | 2018 | 1116 | 0.11 | Why? |
| Organizational Policy | 1 | 2016 | 694 | 0.11 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.11 | Why? |
| Mammography | 1 | 2014 | 410 | 0.11 | Why? |
| Sepsis | 2 | 2018 | 3517 | 0.10 | Why? |
| Simplified Acute Physiology Score | 2 | 2021 | 102 | 0.10 | Why? |
| Proportional Hazards Models | 2 | 2021 | 6543 | 0.10 | Why? |
| Antipsychotic Agents | 1 | 2018 | 887 | 0.10 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.09 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.09 | Why? |
| Self Report | 1 | 2021 | 3802 | 0.09 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.09 | Why? |
| Immunoglobulins, Intravenous | 1 | 2021 | 2705 | 0.09 | Why? |
| Databases, Factual | 2 | 2021 | 6248 | 0.09 | Why? |
| Risk | 1 | 2021 | 5288 | 0.09 | Why? |
| Acute Lung Injury | 1 | 2017 | 904 | 0.09 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.09 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.09 | Why? |
| Oleic Acid | 1 | 2007 | 43 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.08 | Why? |
| Cognition Disorders | 1 | 2012 | 574 | 0.08 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.08 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.08 | Why? |
| Aged | 13 | 2021 | 215776 | 0.08 | Why? |
| Oseltamivir | 1 | 2010 | 583 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Animals | 10 | 2021 | 78931 | 0.08 | Why? |
| Frailty | 1 | 2018 | 1432 | 0.08 | Why? |
| Survivors | 1 | 2019 | 2619 | 0.08 | Why? |
| Vero Cells | 5 | 2021 | 14117 | 0.08 | Why? |
| Health Services Needs and Demand | 1 | 2021 | 3419 | 0.08 | Why? |
| Skin | 1 | 2018 | 2096 | 0.07 | Why? |
| Mice | 4 | 2019 | 21357 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Liver Diseases | 1 | 2021 | 2698 | 0.07 | Why? |
| Mobile Applications | 1 | 2021 | 3032 | 0.07 | Why? |
| Cross-Over Studies | 2 | 2018 | 867 | 0.07 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2014 | 1458 | 0.07 | Why? |
| Virus Replication | 4 | 2020 | 14331 | 0.07 | Why? |
| Developing Countries | 1 | 2020 | 4283 | 0.07 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.07 | Why? |
| Dengue | 1 | 2017 | 1565 | 0.07 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.07 | Why? |
| Colombia | 2 | 2021 | 1241 | 0.07 | Why? |
| Fever | 1 | 2021 | 7795 | 0.07 | Why? |
| Socioeconomic Factors | 1 | 2021 | 8495 | 0.06 | Why? |
| Critical Care | 4 | 2019 | 14081 | 0.06 | Why? |
| Family | 1 | 2016 | 2909 | 0.06 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.06 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.06 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.06 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 1510 | 0.05 | Why? |
| Registries | 1 | 2021 | 12327 | 0.05 | Why? |
| Time Factors | 5 | 2019 | 31397 | 0.05 | Why? |
| Antigens, Viral | 1 | 2017 | 6298 | 0.05 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.05 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.05 | Why? |
| Lung | 2 | 2017 | 31049 | 0.05 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.05 | Why? |
| Nervous System Diseases | 1 | 2018 | 4092 | 0.05 | Why? |
| Immunohistochemistry | 1 | 2007 | 2275 | 0.05 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.05 | Why? |
| Valine | 1 | 2021 | 359 | 0.05 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.05 | Why? |
| Kinetics | 1 | 2007 | 3238 | 0.05 | Why? |
| Electrophoresis, Gel, Two-Dimensional | 1 | 2018 | 40 | 0.05 | Why? |
| Mycobacterium leprae | 1 | 2018 | 20 | 0.05 | Why? |
| Reflex, Righting | 1 | 2017 | 3 | 0.05 | Why? |
| Swine | 1 | 2007 | 3352 | 0.04 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2007 | 2309 | 0.04 | Why? |
| Rehydration Solutions | 1 | 2017 | 7 | 0.04 | Why? |
| Cell Death | 1 | 2020 | 536 | 0.04 | Why? |
| Comparative Effectiveness Research | 1 | 2018 | 178 | 0.04 | Why? |
| Acellular Dermis | 1 | 2017 | 13 | 0.04 | Why? |
| Electrophoresis, Polyacrylamide Gel | 1 | 2018 | 238 | 0.04 | Why? |
| Ghana | 1 | 2021 | 763 | 0.04 | Why? |
| Glucose Transport Proteins, Facilitative | 1 | 2017 | 5 | 0.04 | Why? |
| Hexokinase | 1 | 2017 | 10 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2019 | 391 | 0.04 | Why? |
| Colloids | 1 | 2017 | 49 | 0.04 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.04 | Why? |
| Carbamates | 1 | 2021 | 485 | 0.04 | Why? |
| Honduras | 1 | 2017 | 117 | 0.04 | Why? |
| Cytosol | 1 | 2017 | 77 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.04 | Why? |
| Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
| Pyrrolidines | 1 | 2021 | 558 | 0.04 | Why? |
| Isotonic Solutions | 1 | 2017 | 69 | 0.04 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.04 | Why? |
| Puerto Rico | 1 | 2017 | 177 | 0.04 | Why? |
| Norway | 1 | 2021 | 1004 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2021 | 10697 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.04 | Why? |
| Conscious Sedation | 1 | 2019 | 222 | 0.04 | Why? |
| Russia | 1 | 2021 | 989 | 0.04 | Why? |
| Animals, Newborn | 1 | 2017 | 350 | 0.04 | Why? |
| Memory | 1 | 2017 | 137 | 0.04 | Why? |
| Europe | 3 | 2018 | 12702 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| Geographic Mapping | 1 | 2017 | 247 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.04 | Why? |
| Biological Transport | 1 | 2017 | 290 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.04 | Why? |
| Technetium Tc 99m Sestamibi | 1 | 2014 | 20 | 0.04 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2017 | 239 | 0.04 | Why? |
| Imidazoles | 1 | 2021 | 631 | 0.04 | Why? |
| Chromatography, Affinity | 1 | 2017 | 310 | 0.04 | Why? |
| Culicidae | 1 | 2017 | 239 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.04 | Why? |
| Metagenome | 1 | 2017 | 268 | 0.04 | Why? |
| Random Allocation | 1 | 2017 | 773 | 0.03 | Why? |
| Whole Body Imaging | 1 | 2014 | 116 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.03 | Why? |
| Mosquito Vectors | 1 | 2017 | 351 | 0.03 | Why? |
| Drug Resistance, Multiple | 1 | 2014 | 156 | 0.03 | Why? |
| Rats, Sprague-Dawley | 1 | 2017 | 987 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Mice, Knockout | 1 | 2019 | 1815 | 0.03 | Why? |
| Plasmodium berghei | 1 | 2012 | 27 | 0.03 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 436 | 0.03 | Why? |
| CD11b Antigen | 1 | 2012 | 90 | 0.03 | Why? |
| Hypnotics and Sedatives | 1 | 2019 | 624 | 0.03 | Why? |
| Logistic Models | 2 | 2019 | 9089 | 0.03 | Why? |
| Efficiency, Organizational | 1 | 2016 | 482 | 0.03 | Why? |
| Sex Characteristics | 1 | 2021 | 1120 | 0.03 | Why? |
| Epitope Mapping | 1 | 2017 | 1240 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2019 | 1475 | 0.03 | Why? |
| Heme Oxygenase-1 | 1 | 2012 | 90 | 0.03 | Why? |
| Mastectomy | 1 | 2017 | 536 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2018 | 1165 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2021 | 1530 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 189 | 0.03 | Why? |
| Cell Membrane | 1 | 2017 | 743 | 0.03 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.03 | Why? |
| Professional-Family Relations | 1 | 2016 | 424 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| Chemotherapy, Adjuvant | 1 | 2014 | 606 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.03 | Why? |
| Cysteine Endopeptidases | 1 | 2020 | 1557 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Cell Survival | 1 | 2017 | 1581 | 0.03 | Why? |
| Sequence Alignment | 1 | 2017 | 2109 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2014 | 447 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.03 | Why? |
| Multimodal Imaging | 1 | 2014 | 534 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.02 | Why? |
| Double-Blind Method | 1 | 2021 | 5988 | 0.02 | Why? |
| Radiopharmaceuticals | 1 | 2014 | 763 | 0.02 | Why? |
| Edema | 1 | 2012 | 333 | 0.02 | Why? |
| Endothelium | 1 | 2012 | 460 | 0.02 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.02 | Why? |
| Propensity Score | 1 | 2018 | 2690 | 0.02 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| Blood Transfusion | 1 | 2018 | 1399 | 0.02 | Why? |
| Frail Elderly | 1 | 2018 | 1427 | 0.02 | Why? |
| Neoplasm Staging | 1 | 2014 | 1999 | 0.02 | Why? |
| Proteomics | 1 | 2018 | 2481 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Mutation | 2 | 2017 | 12376 | 0.02 | Why? |
| Chemokines | 1 | 2012 | 1095 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Influenza, Human | 1 | 2010 | 10779 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Leukocytes | 1 | 2012 | 1046 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.02 | Why? |
| Biological Evolution | 1 | 2010 | 641 | 0.02 | Why? |
| Canada | 1 | 2018 | 6018 | 0.02 | Why? |
| Health Resources | 1 | 2018 | 2592 | 0.02 | Why? |
| Genome, Viral | 2 | 2017 | 13157 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2020 | 6902 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Protease Inhibitors | 1 | 2020 | 3630 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2017 | 3129 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2018 | 3023 | 0.02 | Why? |
| Patient Discharge | 1 | 2019 | 5696 | 0.02 | Why? |
| Viral Nonstructural Proteins | 1 | 2020 | 4810 | 0.02 | Why? |
| Membrane Proteins | 1 | 2012 | 1733 | 0.01 | Why? |
| Neoplasms | 1 | 2010 | 17251 | 0.01 | Why? |
| Mice, Inbred C57BL | 1 | 2012 | 5542 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| RNA, Messenger | 1 | 2012 | 5131 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.01 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.01 | Why? |
| Chloroquine | 1 | 2012 | 3152 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Child | 2 | 2018 | 70012 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Depression | 1 | 2019 | 14116 | 0.01 | Why? |
| Virus Shedding | 1 | 2010 | 5834 | 0.01 | Why? |
| Anxiety | 1 | 2019 | 17311 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2016 | 43792 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.01 | Why? |
| Child, Preschool | 1 | 2010 | 36283 | 0.00 | Why? |